In this episode of InsideTracker, host Gil Blander talks with Karl Pfleger, a longevity-focused angel investor and biotech advocate, about the rapidly growing aging biotechnology sector. Pfleger shares insights on the science, investment trends, and societal shifts driving the field, as well as the innovations that could redefine how we age.

Key Points:

Karl Pfleger explores how longevity biotech is shifting from niche research to a global innovation hub, aiming to prevent age-related decline before it begins. Advances in therapeutics, biomarkers, and investment are driving a new era in healthy aging.

• The Aging Biotech Landscape: Pfleger describes aging biotech as moving from a niche interest to a booming global industry, with breakthroughs in genetics, cell biology, and biomarkers attracting both researchers and investors.
• From Disease Treatment to Prevention: Advances in the field are shifting the focus from treating age-related diseases after they occur to preventing them entirely by targeting the biological mechanisms of aging.
• Investment Trends in Longevity: The industry has seen a surge of funding from venture capital and private investors, with early-stage companies developing drugs, diagnostics, and lifestyle interventions.
• Emerging Therapies and Tools: Pfleger highlights promising innovations such as senolytics (removing aged cells), epigenetic reprogramming, and AI-driven biomarker tracking for personalised health optimisation.
• Ethics, Access, and Education: For longevity biotech to benefit society, Pfleger stresses the importance of equitable access, public education, and regulatory pathways that balance safety with innovation.